Mahdi Abastabar1,2, Ali Jedi2,3, Jacques Guillot4, Macit Ilkit5, Samaneh Eidi6, Mohammad Taghi Hedayati1,2, Tahereh Shokohi1,2, Roshanak Daie Ghazvini7, Ali Rezaei-Matehkolaei8, Farzad Katiraee9, Javad Javidnia3, Bahram Ahmadi10, Hamid Badali1,2. 1. Invasive Fungi Research Center, School of Medicine, Mazandaran University of Medical Sciences. 2. Department of Medical Mycology, Mazandaran University of Medical Sciences. 3. Student Research Committee, Mazandaran University of Medical Sciences. 4. Department of Parasitology, Mycology, Dermatology, EA Dynamyc, UPEC, Ecole nationale vétérinaire d'Alfort. 5. Department of Medical Microbiology, Faculty of Medicine, University of Çukurova. 6. Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad. 7. Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences. 8. Department of Medical Mycology, Faculty of Medicine/Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences. 9. Department of Pathobiology, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran. 10. Department of Medical Laboratory Sciences, Faculty of Paramedical, Bushehr University of Medical Sciences.
Abstract
BACKGROUND: Microsporum canis is a zoophilic species, found to be the most frequently isolated species in animals. M. canis causes sporadic outbreaks of infections in humans, such as the one that occurred in Canada, where more than 1000 human cases were detected over an 8-year period. Despite the medical importance of M. canis infections, there are limited in vitro data on the antifungal susceptibility to antifungal drugs, including new generation triazoles and imidazoles. OBJECTIVE: The aim of the current study was to comprehensively evaluate the in vitro activity of new azoles and comparator drugs against a large panel of M. canis isolates using a microdilution assay. METHODS: The in vitro susceptibility to novel triazoles and imidazoles was compared to that of other antifungal drugs using a large collection of M. canis clinical isolates (n = 208) obtained from patients and animals with dermatophytosis in Iran, France and Turkey. RESULTS: All isolates exhibited high susceptibility to the majority of the tested antifungal agents. However, luliconazole, lanoconazole and efinaconazole, as well as econazole, demonstrated superior activity against all strains in comparis on with the other drugs. CONCLUSION: FDA-approved antifungal drugs, that is luliconazole, efinaconazole and lanoconazole, showed the highest antifungal activity and should be promising candidates for the treatment of dermatophytosis caused by M canis. However, their therapeutic effectiveness remains to be determined in clinical settings.
BACKGROUND:Microsporum canis is a zoophilic species, found to be the most frequently isolated species in animals. M. canis causes sporadic outbreaks of infections in humans, such as the one that occurred in Canada, where more than 1000 human cases were detected over an 8-year period. Despite the medical importance of M. canis infections, there are limited in vitro data on the antifungal susceptibility to antifungal drugs, including new generation triazoles and imidazoles. OBJECTIVE: The aim of the current study was to comprehensively evaluate the in vitro activity of new azoles and comparator drugs against a large panel of M. canis isolates using a microdilution assay. METHODS: The in vitro susceptibility to novel triazoles and imidazoles was compared to that of other antifungal drugs using a large collection of M. canis clinical isolates (n = 208) obtained from patients and animals with dermatophytosis in Iran, France and Turkey. RESULTS: All isolates exhibited high susceptibility to the majority of the tested antifungal agents. However, luliconazole, lanoconazole and efinaconazole, as well as econazole, demonstrated superior activity against all strains in comparis on with the other drugs. CONCLUSION: FDA-approved antifungal drugs, that is luliconazole, efinaconazole and lanoconazole, showed the highest antifungal activity and should be promising candidates for the treatment of dermatophytosis caused by M canis. However, their therapeutic effectiveness remains to be determined in clinical settings.